Author

M. de Beijer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Trapman-Jansen· 1 shared C.-Y. Liao· 1 shared D. Hammerl· 1 shared D. Kortleve· 1 shared D. Roelofs· 1 shared E. H. J. Danen· 1 shared J. A. Demmers· 1 shared J. Michaux· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Trapman-Jansen

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models

D. Kortleve, D. Hammerl, M. van Brakel, R. Wijers, D. Roelofs, K. Kroese, M. Timmermans, C.-Y. Liao, A. Trapman-Jansen, R. Foekens, J. Michaux, M. de Beijer, S. I. Buschow, J. A. Demmers, M. Kok, , R. Debets

This study identifies ROPN1 as a target for TCR-engineered T-cells effective against TNBC in preclinical models and demonstrates their safety and efficacy.

bioRxiv · Jan 10, 2024 · PreprintImmunology